Age: 20-70 years old;
Gender: male or female;
clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients;
The expected survival> 3 months;
Child-Pugh grade in A-level;
KPS score with 50-100 points;
BCLC stage of 0-B;
conform to the indications of hepatectomy;
Viable tumor resection confirmed by two highly qualified surgical doctors;
No other surgical contraindications.
women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment;
Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment;
All patients must be prohibited donation during the treatment process and in 28 days after treatment;
In addition to the subjects, prohibitting other people taking this product.
patients have a good understanding and could coordinate with investigators for the trial.
Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial.

NCT02399033_inc_T1
Person
Age
NCT02399033_inc_T2
Value
20-70 years old
NCT02399033_inc_T3
Person
Gender
NCT02399033_inc_T4
Value
male
NCT02399033_inc_T5
Value
female
NCT02399033_inc_T6
Scope
male or female
NCT02399033_inc_T8
Condition
hepatocellular carcinoma
NCT02399033_inc_T9
Qualifier
clinical or pathological diagnosis
NCT02399033_inc_T10
Condition
HCC
NCT02399033_inc_T11
Qualifier
untreated
NCT02399033_inc_T7
Observation
expected survival
NCT02399033_inc_T12
Value
> 3 months
NCT02399033_inc_T13
Measurement
Child-Pugh grade
NCT02399033_inc_T14
Value
A
NCT02399033_inc_T15
Measurement
KPS score
NCT02399033_inc_T16
Value
50-100 points
NCT02399033_inc_T17
Measurement
BCLC stage
NCT02399033_inc_T18
Value
0-B
NCT02399033_inc_T19
Procedure
hepatectomy
NCT02399033_inc_T20
Observation
indications of hepatectomy
NCT02399033_inc_T22
Negation
No
NCT02399033_inc_T23
Observation
other surgical contraindications
NCT02399033_inc_T24
Person
women
NCT02399033_inc_T25
Observation
reproductive period
NCT02399033_inc_T26
Procedure
contraception
NCT02399033_inc_T27
Temporal
in 28 days before treatment
NCT02399033_inc_T28
Reference_point
treatment
NCT02399033_inc_T29
Temporal
during the treatment process
NCT02399033_inc_T30
Temporal
in 28 days after treatment
NCT02399033_inc_T31
Reference_point
treatment
NCT02399033_inc_T32
Reference_point
treatment
NCT02399033_inc_T33
Scope
in 28 days before treatment, during the treatment process and in 28 days after treatment
NCT02399033_inc_T34
Person
Men
NCT02399033_inc_T35
Procedure
contraception
NCT02399033_inc_T36
Negation
prohibited
NCT02399033_inc_T37
Procedure
sperm donation
NCT02399033_inc_T38
Temporal
during the treatment process
NCT02399033_inc_T39
Temporal
in 28 days after treatment
NCT02399033_inc_T40
Reference_point
treatment
NCT02399033_inc_T41
Reference_point
treatment
NCT02399033_inc_T42
Scope
during the treatment process and in 28 days after treatment
NCT02399033_inc_T43
Procedure
donation
NCT02399033_inc_T44
Negation
prohibited
NCT02399033_inc_T45
Procedure
donation
NCT02399033_inc_T46
Temporal
during the treatment process
NCT02399033_inc_T47
Reference_point
treatment
NCT02399033_inc_T48
Temporal
in 28 days after treatmen
NCT02399033_inc_T49
Reference_point
treatment
NCT02399033_inc_T50
Scope
during the treatment process and in 28 days after treatment